Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 17

January 12, 2022 00:39:58
Episode Cover

Episode 17: Amy Fenton Parker, President and CEO at Batten Disease Support and Research Organization (BDSRA)

Why are advocacy and accessibility so important to rare diseases such as Batten Disease? On this week’s Few & Far Between podcast episode, Biorasi’s...

Listen

Episode 32

August 17, 2023 00:37:05
Episode Cover

Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax

"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...

Listen

Episode 43

September 12, 2024 00:39:18
Episode Cover

Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than...

Listen